Iradimed (NASDAQ:IRMD) Releases Q4 2024 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.420-0.450 for the period, compared to the consensus estimate of 0.400. The company issued revenue guidance of $18.8 million-$19.2 million, compared to the consensus revenue estimate of $19.3 million. Iradimed also updated its FY 2024 guidance to 1.640-1.670 EPS.

Iradimed Stock Down 2.0 %

Iradimed stock traded down $0.97 during midday trading on Friday, hitting $48.30. 32,944 shares of the stock were exchanged, compared to its average volume of 28,110. The company has a fifty day simple moving average of $48.98 and a two-hundred day simple moving average of $45.56. Iradimed has a 52 week low of $39.24 and a 52 week high of $53.99. The stock has a market capitalization of $611.96 million, a PE ratio of 33.08 and a beta of 0.79.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.05. Iradimed had a net margin of 26.12% and a return on equity of 24.59%. The business had revenue of $17.93 million for the quarter, compared to analyst estimates of $17.70 million. During the same quarter last year, the firm earned $0.33 EPS. As a group, equities research analysts anticipate that Iradimed will post 1.47 EPS for the current fiscal year.

Iradimed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 25th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.24%. Iradimed’s dividend payout ratio (DPR) is currently 41.10%.

Analyst Upgrades and Downgrades

Separately, Roth Mkm dropped their target price on shares of Iradimed from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, August 2nd.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.